A Phase II, Open-Label, Multicenter Study of the GARFT Inhibitor AG2037 [pelitrexol] in Patients With Metastatic Colorectal Cancer Who Failed Treatment With a 5-Fluorouracil/Leucovorin Regimen

Trial Profile

A Phase II, Open-Label, Multicenter Study of the GARFT Inhibitor AG2037 [pelitrexol] in Patients With Metastatic Colorectal Cancer Who Failed Treatment With a 5-Fluorouracil/Leucovorin Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2008

At a glance

  • Drugs Pelitrexol (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Dec 2008 Last checked against ClinicalTrials.gov record.
    • 22 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top